Latest news with #PraxisPrecisionMedicines
Yahoo
4 days ago
- Business
- Yahoo
Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX)
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On June 12, Truist Financial analyst Joon Lee maintained a Buy rating on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) without a price target. The company reported in its fiscal Q1 2025 results that it is on track for six major study readouts across four programs over 12 months, and is ready to start the pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025. These include the EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen. A scientist wearing a lab coat, surrounded by vivid blue-themed biopharmaceutical equipment in a research laboratory. Management anticipates topline near-term results for vormatrigine from the RADIANT study in epilepsy by mid-2025, along with the POWER1 study in H2 2025. Vormatrigine is continuing to exhibit competitive differentiation and an ideal profile, bringing a positive light to Praxis Precision Medicines, Inc. (NASDAQ:PRAX). Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company that develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company focuses on two proprietary platforms: Cerebrum and Solidus. While we acknowledge the potential of PRAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Yahoo
6 days ago
- Business
- Yahoo
Truist Financial Remains Bullish on Praxis Precision Medicines (PRAX)
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is one of the 13 Small Cap Stocks Analysts Are Bullish On. On June 12, Truist Financial analyst Joon Lee maintained a Buy rating on Praxis Precision Medicines, Inc. (NASDAQ:PRAX) without a price target. The company reported in its fiscal Q1 2025 results that it is on track for six major study readouts across four programs over 12 months, and is ready to start the pivotal studies in two developmental and epileptic encephalopathy (DEE) programs in mid-year 2025. These include the EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A GoF with elsunersen. A scientist wearing a lab coat, surrounded by vivid blue-themed biopharmaceutical equipment in a research laboratory. Management anticipates topline near-term results for vormatrigine from the RADIANT study in epilepsy by mid-2025, along with the POWER1 study in H2 2025. Vormatrigine is continuing to exhibit competitive differentiation and an ideal profile, bringing a positive light to Praxis Precision Medicines, Inc. (NASDAQ:PRAX). Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is a clinical-stage biopharmaceutical company that develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The company focuses on two proprietary platforms: Cerebrum and Solidus. While we acknowledge the potential of PRAX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
09-06-2025
- Business
- Yahoo
Former head trader of Denver-based investing company pleads guilty to insider trading
DENVER (KDVR) — A Connecticut man pleaded guilty to an insider trading charge on Friday for actions he took while employed at Denver-based firm Irving Investors. Ryan Squillante, 40, of Weston, Connecticut, was employed as the head of equity trading at Irving Investors at the time of the offense, according to the U.S. Attorney's Office for the District of Connecticut. While there, he received 'material non-public information' about some publicly traded companies. Australian hacker sentenced in May arrested by HSI Denver, faces deportation Prosecutors say that Squillante used MNPI on 15 different occasions between August 2022 and May 2023 for his own benefit, profiting about $220,912 from the transactions, according to the attorney's office. The U.S. Attorney's Office for the District of Connecticut provided an example of one of the times Squillante reportedly received MNPI about a clinical-stage biopharmaceutical company called Praxis Precision Medicines. Praxis is traded on the NASDAQ. The prosecutors said that between Feb. 27, 2023, and March 2, 2023, Squillante 'sold short' over 38,000 shares of Praxis for an average price per share of $3.04. On March 3, prosecutors say Squillante announced poor results of the company's drug trial before the market opened. Following that announcement, Squillante 'covered' the same number of shares at an average price of $1.82 per share, making a profit of about $46,421. Squillante pleaded guilty to securities fraud, which has a maximum term of imprisonment of 20 years. He's scheduled to be sentenced on Aug. 29. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
04-05-2025
- Business
- Yahoo
Praxis Precision Medicines First Quarter 2025 Earnings: US$3.29 loss per share (vs US$2.85 loss in 1Q 2024)
Net loss: US$69.3m (loss widened by 75% from 1Q 2024). US$3.29 loss per share (further deteriorated from US$2.85 loss in 1Q 2024). We've discovered 3 warning signs about Praxis Precision Medicines. View them for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 12% from a week ago. It's still necessary to consider the ever-present spectre of investment risk. We've identified 3 warning signs with Praxis Precision Medicines, and understanding these should be part of your investment process. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Globe and Mail
02-05-2025
- Business
- Globe and Mail
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on May 1, 2025, the Compensation Committee of Praxis' Board of Directors granted restricted stock unit awards covering an aggregate of 3,688 shares of its common stock to five new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Inducement Plan). The restricted stock units were granted as inducements material to the employees' entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4). The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an inducement material to such individuals' entering into employment with Praxis, pursuant to Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, subject to each employee's continued employment with Praxis on each vesting date. About Praxis Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit and follow us on Facebook, LinkedIn and Twitter/X.
